[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100481377":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":33,"centralContacts":38,"locations":43,"responsibleParty":59,"collaborators":32,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":65,"acronym":32,"eligibilityCriteria":66,"healthyVolunteers":63,"sex":67,"minAge":68,"maxAge":69,"enrollmentInfo":70,"targetDuration":32,"studyType":73,"phases":74,"briefSummary":76,"conditions":77,"keywords":79,"overallStatus":45,"whyStopped":32,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"NYU Langone Health","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Continuous Glucose Monitoring (CGM)","EXPERIMENTAL","Patients in the CGM group will be instructed to wear a CGM uninterruptedly for 2 weeks duration.",[13],"Device: Continuous Glucose Monitor",{"label":15,"type":16,"description":17,"interventionNames":18},"Blood Glucose Monitoring (BGM)","ACTIVE_COMPARATOR","Patients in the BGM group will be instructed to check their blood glucose utilizing fingerstick glucose monitoring multiple times daily depending on their insulin regimen for 2 weeks duration.",[19],"Device: Blood Glucose Monitor",[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DEVICE","Continuous Glucose Monitor","Manufactured by Abbott Diabetes Care Inc. Administered by trained investigator prior to hospital discharge, left in place for 2 weeks duration, then removed.",[9],[27],"Dexcom G7",{"type":22,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"Blood Glucose Monitor","Self-administered according to investigator instruction.",[15],null,[34],{"name":35,"affiliation":36,"role":37},"Michael Goldstein","NYU Langone Hospital - Long Island","PRINCIPAL_INVESTIGATOR",[39],{"name":35,"role":40,"phone":41,"phoneExt":32,"email":42},"CONTACT","516-663-3511","Michael.Goldstein@nyulangone.org",[44],{"facility":36,"status":45,"city":46,"state":47,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"RECRUITING","Mineola","New York","11501","United States","US",{"type":52,"coordinates":53},"Point",[54,55],-73.64068,40.74927,{"lat":55,"lon":54},[58],{"name":35,"role":40,"phone":41,"phoneExt":32,"email":42},{"type":60,"investigatorFullName":32,"investigatorTitle":32,"investigatorAffiliation":32,"oldNameTitle":32,"oldOrganization":32},"SPONSOR","100481377","effect-of-2-week-continuous-glucose-monitoring-on-glycemic-management-in-patients-new-to-insulin-on-hospital-discharge-100481377",false,"NCT05548205","Effect of 2-Week Continuous Glucose Monitoring on Glycemic Management in Patients New-to-Insulin on Hospital Discharge","Inclusion Criteria:\n\n1. Male or female aged 18-100 years\n2. Known history of type 1 or type 2 diabetes\n3. Admitted to NYU Langone Hospital - Long Island between December 16, 2024- December 31, 2026\n4. New initiation of insulin therapy, including basal insulin regimen, basal-bolus insulin regimen, or mixed insulin regimen at the time of hospital discharge\n\nExclusion Criteria:\n\n1. Prior to admission use of home insulin therapy\n2. Current use of systemic corticosteroids\n3. Active pregnancy; as pregnancy requires different blood glucose targets, subjects known to be pregnant will be excluded from this study. Subjects will not be tested for pregnancy outside of testing performed in routine medical care; pregnancy will be determined by patient self-reporting. Females of childbearing potential will not be instructed to avoid pregnancy, however if they became pregnant during the study (detected by self-reporting), they will be withdrawn from the study.","ALL","18 Years","100 Years",{"count":71,"type":72},150,"ESTIMATED","INTERVENTIONAL",[75],"NA","The proposed study will be a randomized, prospective, non-blinded study of 120 participants with type 1 or type 2 diabetes that are new-to-insulin on hospital discharge. On hospital discharge, participants will be assigned to either the intervention of wearing a continuous glucose monitor (CGM) for 2 weeks or blood glucose monitoring (BGM) for 2 weeks. They will have a 2-week follow up visit, during which insulin doses will be adjusted as needed, and a 3-month follow-up visit, at which point HbA1c will be measured.",[78],"Diabetes",[9],"2026-08-06",{"date":82,"type":83},"2026-08-07","ACTUAL",{"date":85,"type":83},"2024-12-16",{"date":87,"type":72},"2027-04-30",{"name":5,"class":6},1]